FDA
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cogent (COGT)
-
-
-
-
-
-
-
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
-
-
-
-
-
-
-
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
-
-
-
-
-
-
-
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
-
-
-
-
-
-
-
Pre-Open Stock Movers 12/23: (OCGN) (UAVS) (SUPN) (CLNE) (CLRB) (FUBO) (NKLA) (more...)
-
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

